- Home
- CRDL vs CIA Comparison
CRDL vs CIA Comparison
Compare CRDL & CIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRDL | CIA |
|---|---|---|
| Founded | 2017 | 1969 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.1M | 264.9M |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CRDL | CIA |
|---|---|---|
| Price | $1.33 | $4.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 428.6K | 67.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $255,616,000.00 |
| Revenue This Year | N/A | $3.10 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $28.23 |
| Revenue Growth | N/A | ★ 4.33 |
| 52 Week Low | $0.88 | $3.25 |
| 52 Week High | $1.71 | $6.40 |
Technical Indicators
Market Signals| Indicator | CRDL | CIA |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 39.52 |
| Support Level | $0.94 | $4.53 |
| Resistance Level | $1.40 | $5.59 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 50.00 | 19.31 |
Price Performance
Historical ComparisonAbout CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
About CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.